- Home
- SGA vs IFRX Comparison
SGA vs IFRX Comparison
Compare SGA & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- IFRX
- Stock Information
- Founded
- SGA 1986
- IFRX 2007
- Country
- SGA United States
- IFRX Germany
- Employees
- SGA N/A
- IFRX N/A
- Industry
- SGA Broadcasting
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- IFRX Health Care
- Exchange
- SGA Nasdaq
- IFRX Nasdaq
- Market Cap
- SGA 78.8M
- IFRX 86.0M
- IPO Year
- SGA 1992
- IFRX 2017
- Fundamental
- Price
- SGA $11.96
- IFRX $1.19
- Analyst Decision
- SGA
- IFRX Strong Buy
- Analyst Count
- SGA 0
- IFRX 5
- Target Price
- SGA N/A
- IFRX $9.80
- AVG Volume (30 Days)
- SGA 9.2K
- IFRX 7.6M
- Earning Date
- SGA 11-06-2025
- IFRX 11-10-2025
- Dividend Yield
- SGA 8.53%
- IFRX N/A
- EPS Growth
- SGA N/A
- IFRX N/A
- EPS
- SGA 0.05
- IFRX N/A
- Revenue
- SGA $109,822,000.00
- IFRX $73,729.00
- Revenue This Year
- SGA N/A
- IFRX N/A
- Revenue Next Year
- SGA $5.37
- IFRX $1,216.24
- P/E Ratio
- SGA $245.58
- IFRX N/A
- Revenue Growth
- SGA N/A
- IFRX N/A
- 52 Week Low
- SGA $10.75
- IFRX $0.71
- 52 Week High
- SGA $14.27
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- SGA 44.82
- IFRX 44.61
- Support Level
- SGA $11.35
- IFRX $1.10
- Resistance Level
- SGA $12.07
- IFRX $1.23
- Average True Range (ATR)
- SGA 0.29
- IFRX 0.18
- MACD
- SGA -0.00
- IFRX -0.02
- Stochastic Oscillator
- SGA 49.55
- IFRX 9.52
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.